Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Cetuximab Injection [Erbitux]
DRUG
2 trials
Sponsors
Shanghai Henlius Biotech
, West China Hospital
Conditions
BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
CRC
Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
Phase 1
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
NCT05019534
West China Hospital
BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
Start: 2021-08-15
End: 2022-12-01
Target: 12
Updated: 2022-05-19
Phase 2
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
NCT04984369
Shanghai Henlius Biotech
CRC
Start: 2021-08-11
End: 2025-01-15
Target: 50
Updated: 2023-08-21
Related Papers
Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer.
2025-11-12